Moderna said the move is inconsistent with previous feedback from the FDA on the experimental influenza shot, called mRNA-1010.

Moderna said the move is inconsistent with previous feedback from the FDA on the experimental influenza shot, called mRNA-1010.

The move comes amid RFK Jr.'s relentless efforts to enact his anti-vaccine agenda.

CEO Stephane Bancel said the letter refusing review did not cite 'any safety or efficacy concerns'.